FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)

The U.S.

Food and Drug Administration (FDA) on Friday approved Novartis AG's (NYSE:NVS) Pluvicto for its radioligand therapy to be used alongside an androgen receptor pathway inhibitor.

This combination is approved for metastatic hormone-sensitive prostate cancer (mHSPC) patients.

FDA Expands Pluvicto To Earlier Prostate Cancer Setting Consequently, the eligible patient base for the therapy has nearly doubled.

Previously, the treatment was established for a later stage known as metastatic castration-resistant prostate cancer.